Search results
Results from the WOW.Com Content Network
Drugs in this class substantially increase HDL cholesterol, lower LDL cholesterol, and enhance reverse cholesterol transport. [citation needed]CETP inhibitors inhibit cholesterylester transfer protein (CETP), which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL).
It increases HDL levels by 30%, as compared to 60% by torcetrapib. [22] Two CETP inhibitors were previously under development. One was Merck's MK-0859 anacetrapib, which in initial studies did not increase blood pressure. [23] In 2017, its development was abandoned by Merck. [24] The other was Eli Lilly's evacetrapib, which failed in Phase 3 ...
Torcetrapib acts (as a CETP inhibitor) by inhibiting cholesterylester transfer protein (CETP), which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL cholesterol levels and reduces LDL cholesterol levels.
Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia.In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).
Evacetrapib was a drug under development by Eli Lilly and Company (investigational name LY2484595) that inhibits cholesterylester transfer protein (CETP inhibitor).CETP collects triglycerides from very low-density lipoproteins (VLDL) or low-density lipoproteins (LDL) and exchanges them for cholesteryl esters from high-density lipoproteins (HDL), and vice versa, but primarily increasing high ...
Other CETP inhibitors: [citation needed] Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases in blood pressure and had net cardiovascular detriment. Dalcetrapib was developed by Hoffmann–La Roche until May 2012. It did not raise blood pressure and did raise HDL, but it showed no clinically meaningful ...
CETP inhibitors (cholesteryl ester transfer protein), 1 candidate is in trials. (Anacetrapib) It is expected that these drugs will mainly increase HDL while lowering LDL; Squalene synthase inhibitor; ApoA-1 Milano; Succinobucol (AGI-1067), a novel antioxidant, failed a phase-III trial.
Dalcetrapib [4] (INN, codenamed JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. [5] [6] DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development ...